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MLLT1 YEATS domain mutations in clinically
distinctive Favourable Histology Wilms tumours
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Wilms tumour is an embryonal tumour of childhood that closely resembles the developing
kidney. Genomic changes responsible for the development of the majority of Wilms tumours
remain largely unknown. Here we identify recurrent mutations within Wilms tumours that
involve the highly conserved YEATS domain of MLLT1 (ENL), a gene known to be involved in
transcriptional elongation during early development. The mutant MLLT1 protein shows altered
binding to acetylated histone tails. Moreover, MLLT1-mutant tumours show an increase in
MYC gene expression and HOX dysregulation. Patients with MLLT1-mutant tumours present
at a younger age and have a high prevalence of precursor intralobar nephrogenic rests. These
data support a model whereby activatingMLLT1mutations early in renal development result in
the development of Wilms tumour.
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W
ilms tumour (WT), the most common embryonal
neoplasm of the childhood kidney, has long intrigued
investigators by its histologic similarity to the
developing kidney1. WTs are also noteworthy for their
associated precursor lesions known as perilobar and intralobar
nephrogenic rests (PLNR, ILNR)2. Favourable histology Wilms
tumours (FHWT) represent 95% of WT; the remaining 5%
develop an additional clonal event (most commonly TP53
mutation) resulting in unfavourable histology characterized as
anaplasia (nuclear hyperchromasia and pleomorphism with
polyploid mitoses)3,4. Molecular alterations long known to
contribute to WT development include mutations and/or
deletions involving WT1, WTX, CTNNB1 and loss of
imprinting or loss of heterozygosity (LOH) at 11p15 (reviewed
in ref. 5). However, the genomic changes responsible for the
development of most WTs remain unknown. The National
Cancer Institute’s ‘Therapeutically Applicable Research
to Generate Effective Treatments’ (TARGET) initiative seeks to
identify therapeutic targets for high-risk paediatric tumours
through comprehensive characterization and integrative analyses
(http://ocg.cancer.gov/programs/target). The ongoing High Risk
TARGET Wilms Tumours include two groups: FHWT that
subsequently relapsed and anaplastic WT.
We report in-frame insertion/deletion MLLT1 mutations in
FHWT that are absent in other TARGET paediatric tumour types.
These MLLT1 mutations were associated with changes in binding
to H3K9ac, evidence of HOX and MYC (MYC-C) expression
dysregulation, and were often accompanied by CTNNB1mutations
and evidence of Wnt pathway activation. Further, patients
with MLLT1 mutations presented at a younger age and were
associated with ILNR rather than PLNR. We conclude that
activating MLLT1 mutations accompanied by Wnt activation early
in renal development result in the development of Wilms tumour.
Results
Identification and characterization of MLLT1 variants. As we
recently reported, analysis of 77 FHWT by whole genome
sequencing (WGS, 58 patients) or whole exomic sequencing
(WES,19 patients) identified 825 high-quality somatic, non-
synonymous variants, with an average of 11 candidate mutations/
case (range 2–42) (ref. 6). Six variants (all identified by WGS)
involved MLLT1, a gene not previously reported to be involved in
WT. Each mutation was verified by Sanger sequencing of PCR
products spanning the variants (Fig. 1). Other verified mutations
identified include somatic single nucleotide variants (SNVs) or
small deletions in WT1 (three patients, 4.5%), CTNNB1 (five
patients, 6.5%), WTX (also known as FAM123B or AMER1, five
patients, 6.5%), DROSHA (seven patients, 10%), DGCR8 (three
patients, 4.5%), and SIX1 or SIX2 (eight tumours, 10%)6. Two
tumours withMLLT1 mutations also had CTNNB1 mutations; no
MLLT1-mutant tumours had accompanying WT1, WTX,
DROSHA, DGCR8, SIX1, or SIX2 mutations (Supplementary
Table 1). These represent all genes with verified variants in at
least four patients with FHWT (45%); the full TARGET high-
risk Wilms tumour data, including 125 tumours (both favourable
histology and anaplastic tumours) and including verified variants
present at lower frequencies, will be reported in full when these
data become available.
Four cases had the identical nine nucleotide in-frame insertion
(AACCACCTG) at MLLT1 position c.343_351 (p.117_
118insNHL) of the transcript NM_005934.3. Two mutations
were nearby in-frame deletions, one with deletion of six
nucleotides at position c.335_340 (p.112_114PPV4L) and one
with a seven-nucleotide deletion and a one-nucleotide insertion at
position c.333_339 (p.111_113NPP4K) (Supplementary Table 1).
The MLLT1 mutations were present in 49–73% of the sequencing
reads and reverse transcription PCR (RT–PCR) analysis found
expression of both wild-type and mutant alleles. Similar MLLT1
insertion/deletion variants were not identified in other TARGET
tumours (neuroblastoma, osteosarcoma, acute lymphocytic and
myelogenous leukaemia, unpublished), nor have they been
reported in dbSNP 134 or 135 (ref. 7), COSMIC v69 (ref. 8), or in
the 1000 Genomes Pilot Projects 1, 2, and 3 (ref. 9). The PROVEAN
algorithm10 predicted these MLLT1 mutations to be deleterious
(scores o 10). PCR amplification followed by sequencing
identified an additional MLLT1 p.117_118insNHL mutation in 1/
19 tumours originally characterized by WES, for a total of 7 MLLT1
mutations in 77 discovery set tumours (11%) (Supplementary
Table 1). No germline MLLT1 mutations were identified.
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Figure 1 | MLLT1 variant verification. (a) Base-pairs (242) of genomic DNA were amplified and the product was detected by capillary electrophoresis.
Eight representative samples with three containing additional larger bands identifying insertion mutations (lanes 2, 5 and 6) are shown. Samples with novel
bands were confirmed by Sanger sequencing. (b) The relative expression of the mutant and wild-type alleles was determined using RT–PCR and
primers designed to amplify exons 4 and 5 of the MLLT1 gene (NM_ 005934) with detection by capillary electrophoresis. The normal allele is represented
by a peak atB175 bp (top panel). Two samples show expression of a shorter allele corresponding to deletion mutations (second and third panels) and one
sample shows expression of a longer allele (bottom panel) corresponding to an insertion mutation. It should be noted that the mutant alleles are expressed
at approximately the same level as the normal alleles. (c) Samples with abnormal bands identified following PCR amplification were confirmed by Sanger
dideoxy sequencing. Shown are three samples including the reference sequence on top (NM_005934.3), a 6-nucleotide deletion in the middle
(c.335_340delCGCCCG) and a 9-nucleotide duplication on the bottom (c.343_351dupAACCACCTG). The base-pair positions have been aligned to show
that these affect the same domain.
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Copy number and gene expression analysis. Copy number loss
at 19p13 (the chromosomal location of MLLT1) was not identi-
fied in any of the 77 FHWT; five non-mutant tumours had gain of
19p13 due to gain of all or the majority of chromosome 19.
Segmental copy number loss was identified forWT1 (14 tumours,
three showing loss of small segments containing all or part
of WT1 and the remainder loss of the majority or all of chro-
mosome 11) and WTX (19 tumours, 14 showing loss of small
segments containing all or part ofWTX and the remainder loss of
the majority or all of the X chromosome) (Fig. 2, Supplementary
Table 1). Gene expression analysis was available for 75 of the 77
tumours (one MLLT1-mutant tumour and one MLLT1 wild-type
tumour did not pass quality control). As we recently reported
within the same 75 tumours, unsupervized analysis using non-
negative matrix factorization (NMF) resulted in k¼ 6 clusters
having the highest cophenetic correlation (0.95) after k¼ 2
(ref. 6). We are now able to identify five of six MLLT1-mutant
tumours within NMF cluster 3 (Fig. 2). Comparison of global
gene expression of MLLT1-mutant tumours with 69 MLLT1
wild-type tumours yielded 96 genes significantly differentially
expressed (two-class unpaired significance analysis of microarrays
qo0.05, Bonferroni-corrected Student’s t-test p valueo0.05, fold
change 42, Supplementary Table 2). Noteworthy was the
significantly increased expression of HOXA13, HOXB6, HOXB7,
MYC, PRAC, IRX3 and PITX2, and decreased expression of
HOXD10 and HOXD11 (Fig. 2). Of particular interest was the
high expression of HOXA13 (fold change 128), a gene not
expressed in the remaining FHWT nor in the cap mesenchyme of
the developing kidney11. The expression of HOXA13 mRNA has
been shown to require the expression of the immediately adjacent
lncRNA HOTTIP (refs 12,13). Six MLLT1-mutant tumours and
six randomly selected MLLT1-wild-type FHWTs were analysed
by quantitative reverse transcription PCR, which confirmed
increased expression of both HOXA13 and HOTTIP in MLLT1-
mutant tumours (Fig. 3a). Increased expression of other lncRNA/
target pairs, including PRAC and its adjacent lncRNA HOXB-AS
(PRAC2, NCRNA00253) (ref. 14) and IRX5 and its adjacent
lncRNA CRNDE (ref. 15) was also observed (Supplementary
Table 2, Fig. 2). The increased expression of these critical
lncRNAs detected with array analysis is particularly noteworthy
because lncRNAs are not usually expressed at levels detectable
using these methods.
To validate the functional impact of the MLLT1 mutations on
gene expression, we transfected the MLLT1 p.117_118insNHL
and p.112_114PPV4K mutant constructs alone or at a 1:1 ratio
with the wild-type MLLT1 construct into the embryonic kidney
cell line HEK293. Both HOXA13 and HOTTIP were significantly
upregulated in the cells transfected with either of the mutant
MLLT1 genes alone and in the cells transfected with the 1:1 ratio
of mutant:wild-type MLLT1 (Fig. 3b) compared with the vector
transfected control cells and the cells transfected with wildtype
alone. To confirm that theMLLT1mutations did not alter protein
stability, cell lysates from the transfected cells were evaluated by
western analysis at 24 48, and 72 h (Fig. 3c and Supplementary
Fig. 2), revealing no significant differences in mutant protein
expression levels.
MLLT1 mutation clinical and genetic correlations. The
TARGET FHWT cases were selected as high risk on the basis of
their clinical recurrence. To determine the frequency of MLLT1
mutations overall in FHWT, we screened a validation set of 475
FHWT by PCR amplification and sequencing. MLLT1 insertion
or deletion mutations were found in 19/475 tumours (4%). The
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Figure 2 | Unsupervized analysis of gene expression data. Non-negative Matrix Factorization (NMF) analysis of 75 FHWTresulted in 6 clusters with the
highest cophenetic correlation (0.95) after k¼ 2. Five of sixMLLT1 mutant tumours with available gene expression data occurred in NMF cluster 3, and two
were accompanied by CTNNB1 mutations. This cluster also contained four tumours with mutation or small segment deletion of WT1, all of which also had
either a mutation of CTNNB1 or small segment deletion or mutation of WTX. This cluster also contained a substantial number of tumours with retention of
imprinting of 11p15 (including all MLLT1-mutant tumours). The sequencing and copy number data is provided in Supplementary Table 1. The predicted
membership in gene expression subsets previously reported5 is provided. (Subsets 1 and 2 were low risk tumours and are therefore not represented in
TARGET, Subsets 3 and 4 are highlighted in green and blue, respectively, and Subset 5 in white). Illustrated at the bottom are the expression patterns of
genes of interest that were highly significantly differentially expressed between MLLT1-mutant and wild-type tumours.
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p.117_118insNHL mutation was identified in 13/19 tumours.
Three identical new variants were also identified as
p.117_118insHHL. The remaining three were deletion mutations
at p.111–112 (Table 1). MLLT1 mutations were observed in 6%
(9/139) of FHWT that recurred, compared with 3% (10/336) of
FHWT that did not recur. Although this suggests an association
between MLLT1 mutation and relapse, this difference does not
meet statistical significance. There was also no detectable
correlation between the specific MLLT1 mutation and relapse.
The clinical, pathologic and molecular details of the 19 FHWT
carrying somatic MLLT1 mutations compared with the entire
group of 475 FHWT are provided in Table 1. The median age at
diagnosis of the patients with and without MLLT1 mutations was
12 and 44 months, respectively, (Po0.0001, Wilcoxon test).
There was also a significant correlation betweenMLLT1 mutation
status and nephrogenic rest status. Of MLLT1-wild-type tumours,
23 and 21% were associated with ILNRs and PLNRs, respectively;
in contrast, 10/19 (53%, P¼ 0.011) MLLT1-mutant tumours
arose in ILNRs, and 0/19 (P¼ 0.019) arose in PLNRs (Fisher’s
exact test). Four MLLT1-mutant tumours arose in kidneys with
multiple ILNRs, a feature thus far predominantly recognized in
patients with syndromes associated with germline WT1 muta-
tions. Of note, in 5/7 MLLT1-mutant tumours in the discovery
set, the comparator constitutional sample was adjacent normal
kidney and lacked the mutation. A source of constitutional DNA
was available for the four cases in the validation set that had
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Figure 3 | Quantitative RT–PCR for HOTTIP and HOXA13. (a) FHWT samples with MLLT1 mutations (n¼ 6; red) and randomly selected MLLT1-wild-type
FHWT (n¼ 10; blue) were evaluated for HOTTIP and HOXA13 expression levels by RT–PCR normalized to endogenous GAPDH levels. A FHWT lacking
MLLT1 mutation was used as the reference sample for calculating the relative quantitation (RQ) value. Samples were run in duplicate and the error bars
represent the s.e.m. of the RQ values. The data are presented in log scale. Note that for tumours that lack expression a bar is not visible. (b) HEK293 cells
transfected with empty vector (Ctl), wild-type MLLT1 (WT), a 1:1 ratio of wild-type MLLT1 and either p.117_118insNHL (upper panels) or p.112_114PPV4K
(lower panels), or only mutant p117_118insNHL or p.112_114PPV4K is shown. RNA was isolated 24, 48 and 72 h after transfection, and the expression
levels of HOXA13 and HOTTIP were normalized to endogenous GAPDH levels. The ddCt value for the control sample at 24 h was used as the reference
sample for calculating the RQ value in each sample for each gene. Three independent experiments were performed for each transfection and the error bars
represent the s.e.m. of the RQ values. (c) HEK293 cells transfected with wild-type MLLT1 or mutant MLLT1 (p117_118insNHL). Lysates were collected at 24,
48, and 72 h for western blotting with a MLLT1 (left) or beta-actin (antibody). The mutant protein was not significantly differentially expressed compared
with the wild-type protein at any of the time points evaluated. Results for p.112_114PPV4K likewise demonstrated no significant difference in levels of
protein expression.
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multiple ILNRs (two from peripheral blood and two from
adjacent normal kidney) and these samples likewise lacked
MLLT1 variants by PCR amplification and sequencing. Sufficient
DNA was available on 16/19 MLLT1-mutant tumours to perform
mutation analysis for WT1, CTNNB1, WTX, DROSHA, DGCR8,
and SIX1/2 and this revealed five CTNNB1 mutations, one WTX
mutation, and no WT1 DROSHA, DGCR8, or SIX1/2 mutations.
A different prevalence of other genetic markers was identified
in MLLT1-mutant tumours. Overall, 81% of all FHWT have
either LOH or loss of imprinting at ICR1 on 11p15 as determined
by methylation analysis5; in comparison, only 2/18 (11%) FHWT
with MLLT1 mutations with available material demonstrated
such changes (Table 1). LOH of 1p and 16q are known to be
associated with relapse in patients with FHWT16. Information
regarding 1p and 16q LOH analysis performed prospectively
during the protocol was available for 11/19 MLLT1-mutant
tumours, and neither was found. Similarly, 1q gain is present in
57 and 24% of patients with FHWT that relapsed and do not
relapse, respectively17. 1q gain was identified in 1/15 MLLT1-
mutant FHWT (see methods). Thus, although MLLT1 mutation
was often associated with poor outcome, this association was
independent of other prognostic markers.
MLLT1 protein evaluation. The MLLT1 locus encodes a 559aa
protein from 12 exons and is one of over 100 proteins that
contain a YEATS domain. The domain name is derived from the
five proteins first discovered in either Saccharomyces cereviseiae
or humans, including Yaf9 (YEATS4, GAS41), ENL (MLLT1,
YEATS1), AF9 (MLLT3, YEATS3), Taf14 and Sas5. In humans,
MLLT1 and AF9 are the most studied and are highly
homologous18. Using a variety of structural and functional
analyses, Li et al. recently demonstrated the AF9 YEATS domain
to (1) span N-terminal residues 1–138, (2) form an
immunoglobulin fold family b-sandwich with eight antiparallel
b strands separated by nine loops capped by a helices and (3)
function as a reader protein, recognizing and binding H3K9ac
(ref. 19). Given their reported homology19, we used the
crystallographic three-dimensional structure of the AF9 YEATS
domain as a template to construct a computational model for
MLLT1 YEATS domain. The MLLT1 YEATS sequence is 82%
identical to AF9 and has no amino acid insertions or deletions
(Fig. 1a). Therefore the two structures are expected to be
extremely similar, resulting in a highly reliable computational
three-dimensional model for the MLLT1 YEATS domain, with a
QMEAN (qualitative model energy analysis) Z score of þ 0.49.
(The QMEAN Z score ranges from  4 (worse) to þ 4 (best)
with the average QMEAN Z score for high-resolution X-ray
structures being 0) (ref. 20). The AF9 amino acids demonstrated
by Li et al. to bind H3K9ac are located in loops 1, 4 and 6; these
amino acids are identical in MLLT1 (Fig. 4a,b). Important residue
differences between MLLT1 and AF9 involve positions 107 and
111 within loop 8 (L8) and these are the same amino acids
demonstrated by Li et al. to be responsible for binding of AF9 to
the  5 position with respect to the H3K9ac motif (H3K4). It is
striking that allMLLT1mutations specifically affect L8; mutations
involving positions 111 and 112 directly impact L8, and those
involving position 117 insert NHL or the similar NHH into the
b8 strand (both sequences are equally capable of binding with
the adjacent b1 strand in the place of the native NHL), pushing
the native NHL out of b8 and into L8 (Fig. 4a–c). Our
computational homology modelling indicates that all the
mutations could be accommodated within the overall YEATS
fold without significantly distorting it (Fig. 4d). Indeed, when we
produced wild-type and mutant MLLT1 recombinant
polypeptides, the mutations did not significantly affect the
protein’s heat stability measured by differential scanning
fluorimetry (melting temperature with 95% confidence interval
for the mean of three experiments: wild-type Tm¼ 47.3±0.3 C,
p.117_118insNHL Tm¼ 47.1±0.1 C, p.111_113NPP4K
Tm¼ 47.3±0.3 C, p.112_114PPV4L Tm¼ 46.7±0.3 C),
arguing against loss of function through simple YEATS domain
misfolding. (We did not test p.117_118insHHL, because this
mutant was predicted to show the same structure and hence
thermostability and binding characteristics as p.117_118insNHL).
The AF9 YEATS domain has its highest affinity to H3K9ac,
with somewhat lower affinity binding to H3K27 (ref. 19). We
therefore tested the ability of recombinant wild-type and mutant
MLLT1 YEATS domain polypeptides to bind acetylated and non-
acetylated H3K9 and H3K27 using isothermal titration
calorimetry (ITC). Wild-type MLLT1 bound to H3K9ac with a
dissociation constant Kd of 60mM, but failed to bind to
non-acetylated H3K9 (Fig. 4e and Supplementary Fig. 1). The
p.117_118insNHL mutation abolished the interaction with
Table 1 | Features of FHWT with MLLT1 mutations.
Age (months) Relapse Histology Stage Nephrogenic Rests 11p15 Status Protein
22 Relapse Mixed II None ROI p.117_118insNHL
5 Relapse Mixed II ILNR ROI p.117_118insNHL
10 No Blastemal II None ROI p.117_118insNHL
7 No Mixed I None ROI p.117_118insNHL
24 No Blastemal III None LOH p.117_118insNHL
10 Relapse Mixed III ILNR ROI p.117_118insNHL
6 No Mixed II multiple ILNR ROI p.117_118insNHL
1 No Mixed II uncertain ROI p.117_118insNHL
27 Relapse Mixed III None ROI p.117_118insNHL
50 Relapse Mixed III/IV ‘possible’ ROI p.117_118insNHL
5 Relapse Mixed II None ROI p.117_118insNHL
9 No Mixed I ILNR ROI p.117_118insNHL
17 No Mixed I multiple ILNR ROI p.117_118insNHL
12 Relapse Mixed III ILNR ROI p.117_118insHHL
1 No Mixed II multiple ILNR ROI p.117_118insHHL
21 No Mixed I ILNR ROI p.117_118insHHL
20 No Mixed II multiple ILNR ROI p.111_113NPP4T
26 Relapse Mixed III ILNR ROI p.111_113NPP4K
77 Relapse Mixed III None LOI p.112_114PPV4L
ILNR, Intralobar nephrogenic rest; LOH, loss of heterozygosity; LOI, Loss of imprinting; ROI, retention of normal imprinting.
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H3K9ac, whereas p.112_114PPV4L weakened it (Kd¼ 107mM).
The p.111_113NPP4K mutation did not affect the binding
affinity with H3K9ac (Kd¼ 57 mM), but altered the changes in
entropy and enthalpy upon association, suggesting that the
atomic interactions and dynamics differ from wildtype. With
regard to binding to H3K27ac, wild-type MLLT1 showed
substantially reduced affinity compared with H3K9ac (Kd¼ 140
mM,) and did not bind non-acetylated H3K27. The
p.111_113NPP4K mutant polypeptide bound H3K27ac with
an even lower affinity (330 mM) (Supplementary Fig. 1). The
p.112_114PPV4L and p117_118insNHL mutants showed no
detectable binding to H3K27ac under the conditions used. Thus,
the novel MLLT1 mutations we describe have a clear effect on the
capacity of MLLT1 YEATS to interact with H3 tail peptides.
Compared with MLLT1, the AF9 YEATS domain bound H3K9ac
and H3K27 with a higher affinity (Kd of 3.7 and 7.0 mM,
respectively)19. This suggests the possibility that MLLT1 may
require additional or different contacts for high-affinity binding
than the ones tested.
Discussion
MLLT1 is a critical component of the super-elongation complex
(SEC) that regulates mRNA elongation by RNA polymerase II
(RNAPII) during transcription, and hence regulates RNA
expression21–23. Perturbation of transcriptional elongation has
been shown to result in abnormal development and neoplastic
transformation (reviewed in ref. 24). The SEC contains a number
of proteins, including AFF4, MLLT1 and PTFEb, among others.
Mechanistically, the C-terminal region of MLLT1 (or the
homologous AF9) binds to the scaffolding protein AFF4, which
then binds the positive transcription elongation factor b
(PTEFb) and ELL2 through separate domains. The N-terminal
YEATS domain binds the polymerase-associated factor complex
(PAFc), which in turn associates with RNAPII and the chromatin
template. PTEFb functions to phosphorylate the carboxy-terminal
domain of RNAPII to facilitate transcriptional elongation25.
MLLT1 and AF9 therefore bridge PTEFb (C terminus) with PAFc
(N terminus) and thereby with RNAPII, enabling transcriptional
elongation. MLLT1 and AF9 compete with each other for binding
AFF4 at their C terminus and exist in separate SEC complexes23;
however, the functional differences between MLLT1- and
AF9- bearing SEC complexes are not clear. Support for a
critical role for MLLT1 within cellular biochemistry is provided
by genetic ablation experiments in which MLLT1-deficient
embryos die extremely early in utero, even before implantation26.
The MLLT1 and AF9 genes were originally recognized through
their participation in chromosomal translocations that fuse their
C-terminal domains (eliminating their YEATS domain) in-frame
with the N terminus of MLL (eliminating the histone H3K4
methyltransferase activity but retaining the chromatin
template binding function) within acute leukaemia27,28. These
translocations result in bridging of PTEFb with RNAII similar to
that described above, yet with important differences. The
N terminus of MLL (which itself is able to bind PAFc and to
the chromatin template of MLL-specific targets) fuses with
MLLT1 (or AF9), thereby again bridging RNAPII with SEC and
enabling the transcription of MLL target genes such as MEIS and
HOXA9 (refs 21–23,29). It has long been speculated that the
YEATS domain likewise functions by binding the chromatin
template30,31; if this is the case, the specific genetic targets of
MLLT1 likely differ from those of MLL.
In addition to AFF4 of the SEC, the C terminus of both MLLT1
and AF9 also bind to DOT1L19,32–34, which is the sole enzyme
responsible for H3K79 methylation35,36. DOT1L was originally
thought to be part of the SEC complex, however, evidence now
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Figure 4 | MLLT1 computational sequence and structure analysis. (a) The
sequences of the MLLT1 and AF9 YEATS domains are provided. Residues
forming the YEATS domain are underlined in red. Identical residues are
highlighted in blue. The secondary structural elements, including the b
strands and intervening loops described for AF9 (ref. 19) are provided. The
recognition sites for H3K9ac by AF9 are indicated with a black diamond;
residue differences at positions 107 and 111 that are also recognition sites
for H3K4 by AF9 are indicated with a red diamond19. Arrows indicate the
MLLT1 mutations identified in the current study. (b) Homology model of the
MLLT1 YEATS domain (cyan), superimposed on AF9 YEATS (orange) bound
to H3K9ac (yellow stick model; PDB 4TMP). The motifs in which the indels
occur are shown in blue and magenta letters. The b1, b7, b8 strands and L8
loop are designated (see text). (c) Amino acid changes between AF9 and
MLLT1 in the L8 loop affect the recognition of the N-terminal region of
acetylated lysine motifs. Residue differences (H4N) between AF9 and
MLLT1 at positions 107 and 111 are highlighted in the superimposition of the
AF9 crystal structure (PDB 4TMP; orange) with our homology model of
MLLT1 YEATS (magenta). (d) The MLLT1 mutations are predicted to
specifically affect the L8 loop. Computational homology models are
coloured cyan (wild-type MLLT1), magenta (p.111_113NPP4K), green
(p.112_114PPV4L) and blue (p.117_118insNHL). p.117_118insHHL is
predicted to produce the same conformation and phenotype as
p.117_118insNHL, because N/H117 are solvent exposed at the back of b8.
(e) Effect of MLLT1 mutations on binding H3K9ac, measured by ITC,
performed in triplicate. Shown are integrated heats resulting from binding of
H3K9ac to MLLT1 wild-type (black), p.111_113NPP4K (magenta),
p.112_114PPV4L (green) and p.117_118insNHL (blue). Heats resulting from
peptide being titrated into buffer are in grey. Inlay: ITC data adjusted to
baseline and offset for better visibility.
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suggests that the interaction between MLLT1/AF9 and AFF4
competes with the binding of MLLT1/AF9 with DOT1L
(refs 22,23). Li et al. recently demonstrated that the AF9
N-terminal YEATS domain specifically binds H3K9ac, bridging
the chromatin template with DOT1L, resulting in H3K79
trimethylation, and hence transcriptional activation of
associated genes19. They thereby establish that the AF9 YEATS
domain serves as an acetyl-lysine reader protein and suggest that
it functions similarly with respect to SEC (ref. 19). The 480%
homology between AF9 and MLLT1 YEATS domain supports a
similar function for MLLT1. MLLT1 has been previously
demonstrated to bind to histones 1 and 3, however the
preferred moiety for binding has not yet been identified30.
In the current study, we identified recurrent MLLT1 mutations
that all target L8 of the YEATS domain. We demonstrated that
wild-type MLLT1 indeed binds H3K9ac and that the MLLT1
mutations result in proteins with altered binding to H3K9ac.
Therefore, our binding assays confirm that L8 plays an important
role in modulating the affinity and specificity of the YEATS
domain, and document a functional impact of the recurrent
MLLT1 mutations. However, even wild-type MLLT1 binds to
H3K9ac with a much lower affinity than does AF9. Therefore, it
remains possible, if not likely, that H3K9ac may not be the histone
acetyl-lysine that MLLT1 binds to with the highest affinity. The
underlying complexity of the functional impact of MLLT1
mutation is also suggested by the fact that reduced binding of
AF9 with H3K9ac resulted in decreased gene expression19; the
increased expression of critical genes that we report and the
presumed gain of function resulting from MLLT1 mutation are
therefore difficult to explain. One of many possibilities is that
decreased binding of mutant-MLLT1-bearing SEC may result in
increased binding of AF9-bearing-SEC (which has a higher
H3K9ac binding affinity than MLLT1). Further functional
studies are needed to fully explore MLLT1 histone tail binding
specificity. Moreover, the alteration in histone binding may not
fully account for the functional impact of these mutations.
Other than histones, the only other protein known to bind the
N terminus of MLLT1 is PAF1, a member of the PAF
multi-protein complex that binds to the SEC and is also involved
in cell cycle regulation, miRNA processing, H3K4 methylation
and H3K79 methylation37,38. The dysregulation of several HOX
genes and the upregulation of MYC (MYC-C) in MLLT1-mutant
FHWT provide indirect support for an altered interaction
between PAFc and the SEC in MLLT1-mutant tumours, as
these genes are all recognized to be regulated through
transcriptional elongation via the SEC (refs 23,39–41). The
positive effect of the MLLT1 mutations on MYC expression may
contribute to transformation through activation. The PAF
complex is composed of four proteins, PAF1, CTR9, CDC73
and LEO1. Of considerable interest is the recent report of
germline inactivating mutations within the CTR9 gene in three of
35 Wilms tumour families42,43, and the report of the development
of Wilms tumours in patients with germline inactivating CDC73
mutations (hyperthyroidism-jaw tumour syndrome, OMIM
145001) (refs 44,45). These were coupled with somatic
mutations of the remaining alleles, consistent with tumour
suppressor function. Both CTR9 and CDC73 play a negative role
in transcriptional elongation45, therefore inactivating mutations
in these genes and activating mutations of MLLT1 may similarly
result in transcriptional activation. We did not find somatic
mutations in any of the genes in the PAFc in these 77 patients.
Functional studies will be of considerable interest to define the
precise changes in binding between mutant versus wild-type
MLLT1 and components of the PAFc in addition to histones.
The absence of reports of these novel MLLT1 mutations in
other tumours or tissues suggests the possibility that their impact
may be restricted to a specific cellular context. Further, the
observation that these mutations were identified in very young
patients whose tumours arose within ILNR, precursor lesions
thought to develop quite early in renal development2,46, provides
evidence that this particular cellular context may be limited to the
early embryonic kidney. Many WT with WT1 mutations also
present at a young age, occur within ILNRs and develop as early
as the intermediate mesoderm5. Constitutional WT1 mutations
often result in multiple ILNRs and WTs46. These WT1-mutant
tumours of infancy require Wnt pathway activating mutations
(for example, CTNNB1, WTX) for transformation5,47. It is
therefore noteworthy that 37% of the evaluable MLLT1-mutant
tumours (which lacked WT1 mutations and deletions) also had
CTNNB1 or WTX mutations, and MLLT1-mutant tumours all
show a striking increase in expression of PITX2 (Fig. 2), a gene
encoding a homeobox protein whose expression follows canonical
Wnt pathway activation and results in increased proliferation
during early development48,49. The identification of multiple
ILNRs in some patients with MLLT1-mutant WTs is intriguing,
and raises questions regarding the possibility of germline
mutations. We were unable to identify any evidence of MLLT1
germline mutations, even in the MLLT1-mutant tumours
with multiple ILNRs. Nor were we able to identify MLLT1
mutations in normal kidney adjacent to MLLT1-mutant tumours.
Last, one of the authors (VH) provided DNA samples from 48
families with familial WT. These were tested for MLLT1
mutations and all were negative (data not shown). In summary,
we did not find evidence to support the existence of germline
MLLT1mutations in FHWT. It may be speculated that in patients
with ILNRs and whose tumours carried MLLT1 mutations, these
mutations occurred in an undifferentiated cell early in kidney
development. The resulting clone of undifferentiated cells could
remain localized, or as the early kidney grows they could separate
into multiple aggregates, resulting in the subsequent development
of single or multiple ILNRs. WT may then develop within an
ILNR, possibly following mutations resulting in Wnt pathway
activation. This model would predict that, unlike the adjacent
normal kidney tissue we assessed for several patients with
MLLT1-mutant tumours, ILNRs from these patients would carry
the MLLT1 mutation. Unfortunately, ILNR material was
unavailable to test this.
Evidence for HOX dysregulation mediated by MLLT1 mutation
in FHWT is most abundantly seen in the striking and early
overexpression of HOXA13. HOXA13 is not expressed in normal
renal development, and the specific role of HOXA13 over-
expression in WT development is not apparent. However, it is
critical for the development of the distal limbs and the reproductive
system; in fact, HOXA13 mutation is responsible for the rare hand-
foot-uterus syndrome (OMIM 140000). HOXA13 upregulation has
also been shown to be a marker of poor outcome in a number of
adult cancers (reviewed in ref. 50). Mechanistically, the association
between MLLT1 mutation and HOXA13 overexpression seen in
our mutant transfection analysis is supported by the accompanying
increased expression of HOTTIP, a lncRNA that has been reported
to result in transcriptional activation of HOXA13 (ref. 12). The
aberrant expression of critical lncRNAs (and their targets) in
MLLT1-mutant FHWT may simply reflect underlying general
mechanisms affecting both lncRNAs and targets. However, one
might speculate that MLLT1 may participate more broadly in the
regulation of transcription mediated by lncRNAs, in keeping with a
proposed model whereby lncRNAs act as scaffolds that brings
regulatory protein complexes (such as SEC) together into larger
functional units in order to coordinate cell-type-specific gene
expression programmes51.
In summary, we report novel somatic mutations inMLLT1 and
provide evidence that supports a role for MLLT1 mutation in the
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aetiology of a subset of FHWT. Our data indicates that
understanding the function of these MLLT1 mutations could
provide important insight into the function of the YEATS domain
in other proteins, and into transcriptional regulation during early
renal development as well as tumour development.
Methods
TARGET data management. The NCI TARGET initiative specifies and supports
the long-term deposition and maintenance of the data files, methods and quality
control steps involved in the comprehensive genomic analysis of TARGET samples.
The sequencing BAM files from both WES and WGS are deposited in the
Sequence Read Archive at the National Center for Biotechnology Information,
and are accessible through the database of genotypes and phenotypes (dbGAP,
http://www.ncbi.nlm.nih.gov/gap) under the accession number phs000471. Gene
expression, chromosome segmental copy number and the clinical information are
available through the TARGET data matrix (http://target.nci.nih.gov/dataMatrix/
TARGET_DataMatrix.html). These are annotated within MIAME compliant
MAGE-TAB files fully describing the methods, the specimen processing details and
the quality control parameters.
Specimens. Primary, pre-therapy tumour and paired blood or normal kidney
samples from 77 patients registered on NWTS-5 with FHWT who subsequently
relapsed were included in the discovery set. To determine the mutation frequency
and to identify clinical associations, a validation set was identified comprised of a
previously defined case-cohort of FHWTs likewise treated on NWTS-5 (including
those in the discovery set)5. This approach allows for efficient evaluation of
molecular markers in a tumour type characterized by a low rate of relapse. In brief,
a cohort of all 1473 patients with FHWT enroled on NWTS-5 who were treated
according to protocol and who had samples submitted to the NWTSG tumour
bank in 2003 were identified. Following the methods of Prentice52, a random
sample of 33% of the cohort was selected. To this group, 178 cases from the entire
cohort who were known to have relapsed as of 2003 were added. This resulted in a
total of 600 patients, 30% of whom relapsed. Of the 600 cases in the original case-
cohort, 475 continued to have available tumour DNA samples in 2012 and received
adjuvant chemotherapy. (Patients registered on the very low risk protocol who did
not receive adjuvant chemotherapy were removed as all patients with MLLT1
mutation received adjuvant chemotherapy). The validation set included tumours
from these 475 patients, 139 of whom relapsed. The median time to relapse for
FHWT is o1 year, and o1% of patients with FHWT relapse beyond 5 years53.
NWTS-5 closed for accrual in 2002, therefore the clinical outcome data is fully
mature. Written consent was obtained from the parents and the studies were
performed with the approval of the Ann & Robert H. Lurie Children’s Hospital
Institutional Review Board.
Sequencing. WGS was accomplished through the four adaptor library protocol54
and variants were identified through a pipeline that is described on the TARGET
DataMatrix. The variants were filtered retaining all somatic, non-synonymous
variants in exons with a somatic score 4 10, somatic rank X0.1, FET Po0.05.
WES was performed on the Illumina HiSeq platform. Variant calling from the
aligned BAM files was performed using both ATLAS and SAMtools and annotation
and filtering was performed using the SACBE annotation pipeline55,56 as well as
Bambino Version 1.05 (ref. 57). Pipelines for both WGS and WES identified single
missense, insertion and deletion variants in exons.
MLLT1 variant verification. Primers were designed to amplify a 242 base-pair
sequence of genomic DNA that included the sites for both the insertion and
deletions identified. PCR amplification was performed using Platinum PCR
SuperMix High Fidelity (Life Technologies Corporation, Carlsbad, CA). Cycling
conditions were as follows: initial denaturation was performed at 96 C for 2min; 5
cycles were performed at 96 C for 20 s, 60 C for 50 s, and 72 C for 30 s; 30 cycles
were performed at 94 C for 22 s, 55 C for 50 s, 72 C for 30 s; a final extension was
performed at 72 C for 10min. The amplified product was detected using capillary
electrophoresis (QIAxcel Advanced System, Qiagen, Valencia, CA). Positive sam-
ples were confirmed by Sanger sequencing using a Big Dye Terminator v1.1 cycle
sequencing kit (Life Technologies Corporation, Carlsbad, CA) and M13 forward
and M13 reverse primers as sequencing primers. The DNA sequence analysis was
performed with 3130xl Genetic Analyzer Data Collection software v3.0 (Life
Technologies Corporation, Carlsbad, CA).
Forward primer with M13F: 50-TGTAAAACGACGGCCAGTGTGCCCTGA
GAGAGAAGTGG-30
Reverse primer with M13R: 50-CAGGAAACAGCTATGACCTGAAGGTGA
GCTTCTCG-30
MLLT1 gene expression analysis. The relative expression of the mutant and
wild-type alleles was determined using 2-step RT–PCR. Primers were designed to
target exons 4 and 5 of the MLLT1 gene (NM_ 005934). Complementary DNA
was synthesized using the SuperScript VILO cDNA kit from Invitrogen. The
manufacture protocol was followed and 300 ng of total RNA was used per reaction.
Briefly, the complementary DNA (cDNA) synthesis reaction was incubated at
25 C for 10min, 42 C for 120min and 85 C for 5min. The PCR reaction mixture
was assembled from a 2XddPCR Supermix for Probes (Bio-Rad, Cat#1863010),
with a final of concentration of 900 nM for each primer and 3 ul of cDNA in a final
volume of 20 ml. Cycling conditions were as follows: denaturation was performed at
95 C for 10min; 40 cycles were performed at 94 C for 30 s and 59 C for 50 s; a
final extension was performed at 98 C for 10min. The amplified product was
detected using capillary electrophoresis (3130xl Genetic Analyzer, Life
Technologies Corporation, Carlsbad, CA).
MLLT1–RT–PCR—fwd /56-50-FAM/CTGTTCCTGAACCTGGAAGG-30
MLLT1–RT–PCR—rev 50-TGGGTAACATGGGGTAGTCG-30
Chromosome segment copy number analysis. DNA labelling, hybridization, and
array scanning were performed for SNP 6.0 arrays (Affymetrix, Santa Clara, CA)
according to the manufacturer’s protocol and processed with the Affymetrix
Genotyping Console 4.0 software to generate Birdseed .chp and .txt files using the
Birdseed v2 algorithm with the default parameters., Model-based expression ana-
lysis was performed and imported into R for reference normalization to a diploid
reference chromosome determined for each tumour, resulting in a normalized
probe level summarization value and a genotype call for each individual probe58.
Circular binary segmentation was performed in R using the DNAcopy
BioConductor package. Default parameters included nperm¼ 10,000 (the number
of permutations used for Pvalue calculation), a¼ 0.01 (the significance level for the
test to accept change points), and random seed¼ 12,345,678 (the seed for the
random number generator). This resulted in a segmented file for each tumour
sample relative to the corresponding normal sample. Segments containing at least
eight markers in which the log2 value was Zþ 0.5 or r 0.5 were considered
regions of gain or loss, respectively.
Gene expression analysis. RNA labelling, hybridization, and array scanning were
performed according to the manufacturer’s protocol for the Affymetrix U133 plus
2 arrays. Unsupervized analysis was performed using the Non-negative Matrix
Factorization (NMF) Consensus Version 5 (ref. 59), applied to the level 3 data
using the following parameters: k initial, 2; k final, 8; number of clusterings, 20;
maximum number of iterations, 2,000; error function, divergence; random seed,
12,345,6789; stop convergence, 40; stop frequency, 10. Comparisons of gene
expression between two groups of samples were performed using the Significance
Analysis of Microarray Version 4.0 (ref. 60) with the following parameters: two-
class unpaired comparison using the T-statistic test, 200 permutations, and a fold
change cutoff of þ / 2.
Methylation analysis at 11p15. Analysis of the extent of methylation of two
imprint control regions (ICR) on chromosome 11p15 was performed taking
advantage of specific restriction sites recognized by methylation-sensitive enzyme
as previously described61. In brief, DNA was extracted using the Qiagen DNeasy
Blood and Tissue Kit (Qiagen, Santa Clarita, CA) following the manufacturer’s
protocol. DNA was digested with either RsaI, RsaI plus HpaII or RsaI plus MspI
followed by quantitative PCR. Per cent methylation was determined at each locus
by comparing the quantity of amplified product after RsaI and HpaII digestion
with the quantity of amplified product after cutting with RsaI alone. The RsaI and
MspI digest was used to control for complete digestion. Retention of imprinting
was defined as 30–70% methylation of both ICR1 (H19DMR) and ICR2 (KvDMR);
loss of imprinting as 80–100% methylation of ICR1 and 30–70% methylation of
ICR2; LOH as 80–100% methylation of ICR1 and 0–20% methylation of ICR2.
Transfection analysis. The p117_118insNHL and the p.112_114PPV4K muta-
tions were generated using the QuikChange II Site-Directed Mutagenesis Kit
(Agilent Technologies). The wild-type gene in a pCMV6-XL5 vector (OriGene) was
used as the template. This cDNA clone is not tagged and therefore contains the
native stop codon. The primer pairs used to generate the appropriate mutation
were obtained by using the Agilent QuikChange Primer Design software program.
Primers used to generate the c.343_351dupAACCACCTG (p.117_118insNHL)
mutant: sense: 5’-CCGTGAACCACCTGAACCACCTGCGCTGCGAGAAGCT-3’;
antisense: 5’-AGCTTCTCGCAGCGCAGGTGGTTCAGGTGGTTCACGG-3’.
Primers used to generate the c.335_340delCGCCG (p.112_114PPV4L) mutant:
Sense: 5’-CCTGGAAGGCAACCTGAACCACCTGCGC-3’; antisense: 5’-GCGCA
GGTGGTTCAGGTTGCCTTCCAGG-3’.
The mutant strand synthesis reaction, the Dpn I digestion of the amplification
products, and the transformation of the the XL10-Blue Gold ultracompetent cells
were carried out according to the manufacturer’s protocol. Briefly, 45 ul of XL10-
Gold ultracompetent cells were incubated with the b-ME mix, the Dpn I digestion
product was added and incubated on ice for 30min, heat shocked at 42 C for 30 s,
and incubated on ice for 2min. SOC broth was added and incubated at 37 C for
1 h. Then, 100 ul of the culture was spread on a pre-warmed culture plate
containing ampicillin, and incubated overnight at 37 C. The resulting colonies
were transferred to a flask containing 5ml of LB media with ampicillin, and put on
a shaker for 8 h at 37 C. The plasmid was isolated from the cells using the Qiagen
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Plasmid Mini Kit, and was sequenced by using the sequencing primers provided
with the Origene vector to verify the correct mutation.
HEK293 cells (purchased from American Type Culture Collection, Manassas,
VA) were plated to achieve a confluency of 70–90%. The cells were transfected with
the pCMV6-XL5 vector without the gene insert (control), the pCMV6-XL5 vector
with the wild-type gene, the pCMV6-XL5 vector with the mutant gene, or with a 1:1
ratio of the mutant and wild-type genes by using Lipofectamine 2000 according to
the manufacturer’s instructions. Three independent experiments were performed for
each transfection. RNA was isolated from the cells 24, and 48 and 72h after
transfection by using the Qiagen RNA Isolation Kit. Expression of the mutant was
verified with the methodology described above for MLLT1 gene expression analysis.
The expression of selected genes of interest in the transfected HEK293 cells was
performed using quantitative reverse transcription PCR using selected commercially
available TaqMan Gene Expression Assay kits as described below.
Western analysis. The above transfected cells were lysed in RIPA buffer at 24, 48
and 72h after transfection, and the lysates were separated using SDS-polyacrylamide
gel electrophoresis. The proteins were transferred to polyvinylidene fluoride mem-
branes, followed by blocking with 1% bovine serum albumin in PBS with 0.05%
Tween, incubation for 1 h at room temperature with a MLLT1 antibody (1:1,000,
diluted in blocking buffer; HPA031166, lot#R30719, Sigma), and incubation for
30min at room temperature with biotin-labelled secondary antibody (1:2,500 in
blocking buffer; Rabbit AP, AP1000, lot#Y0222, Vector Labs). Beta-actin (primary,
1:5,000, Anti-beta-actin, A5411, lot#093K879, Sigma; secondary, 1:2,500, Mouse AP,
AP2000, lot#W0426, Vector Labs) was used for the loading control under the same
conditions described for MLLT1. Bands were visualized by using the BCIP/NBT Kit
(SK5400, Vector Labs). See Supplementary Fig. 2 for uncropped western blot.
Quantitative RT–PCR. Reverse transcription reactions, RNase inhibition and real-
time PCR were performed according to the manufacturer’s instructions for GAPDH,
HOXA13 and HOTTIP. In brief, RNA was diluted to a concentration of 5 ngml 1
and the reverse transcription reactions were performed using the High Capacity
cDNA Reverse Transcription Kit (Life Technologies, cat# 4368814) and RNase
Inhibitor (Life Technologies, cat# 100021540), per the manufacturer’s instructions.
Non-amplification controls were run once for each RNA sample. Real-time PCR was
performed on 3ml of cDNA, according to the manufacturer’s instructions, using the
TaqMan Universal PCR Master Mix, No AmpErase UNG (Life Technologies,
cat# 4324018) and the 7500 Fast Real-Time PCR System. A non-template control
was run with every plate, for each gene expression assay. The following Taqman gene
expression assays were used: GAPDH (Life Technologies, cat# Hs03929097_g1),
HOXA13 (Life Technologies, cat# Hs00426284_m1) and HOTTIP (Life Technolo-
gies, cat# Hs00955374_s1). GAPDH was used as the endogenous control to calculate
the dCt values for each sample. The ddCt value for the control sample at 24 h was
used as the reference sample for calculating the relative quantitation (RQ) value in
each sample for each gene (RQ¼ 2( ddCt)). The data are shown as the average RQ
and SEM for three independent experiments.
Computational protein structure analysis. The three-dimensional structure of
residues 1–138 of wild-type MLLT1 YEATS was modelled using SwissModel62 based
on the crystal structure of the 82% identical AF9 YEATS domain bound to H3K9ac
(PDB id 4TMP). Mutant MLLT1 YEATS domains were produced using the same
procedure. Models were visualized and analysed using Pymol (www.pymol.org).
Recombinant protein analysis. The codon-optimized DNA sequence coding for
residues 1–138 of human MLLT1 (established using the Gibson assembly method)
was inserted into the pET28 vector with thrombin cleavage site between 6His tag and
protein sequence. Proteins were expressed in Escherichia coli BL21(pLysS) cells.
Expression was induced using 1mM IPTG, and allowed to proceed for 8 h at 20 C.
Wild-type and mutant proteins were purified using Ni-NTA sepharose followed by
size exclusion chromatography (Pharmacia Superdex 75 16/600). Peak fractions were
pooled. For ITC analysis proteins were dialyzed into 50mM Hepes buffer pH 7.4,
300mM NaCl, 5mM b-mercaptoethanol and placed in the measurement cell
(YEATS domain) or the injection syringe (histone peptides) of MicroCal ITC200 and
TA Nano microcalorimeters, at 25 C. Protein concentrations for wild-type,
p.117_118insNHL, p.112_114PPV4L and p.111_113NPP4K mutants were 120,
130, 120 and 90mM, respectively. Peptide concentrations for all measurements were
1.2mM. Thermal stability of wild-type and mutant proteins was probed using a
Roche LightCycler 480II. Wild-type and mutant proteins were kept in the ITC buffer
at concentrations of 7 mM. SyproOrange was used as dye, and temperature was
ramped from 20–95 C. Reported values are mean values of triplicate measurements.
Sequencing of selected genes. Probes to CTNNB1, WT1 and WTX were
designed using RefSeq IDs limited to coding exons and UTRs with probe density
specified at 2x with 98.7% of the target region covered. Pooled libraries were
hybridized to the RNA probes. Post-capture material was purified and enriched
with 10 cycles of PCR. Paired-end 100 base reads were sequenced per pool in a
single lane of an Illumina HiSeq2500 instrument. Single nucleotide variants were
filtered out if they were judged not to be damaging by at least 2/3 of the following
algorithms: SIFT using Ensembl Variant Effect Predictor Version 75 (ref. 63),
PolyPhen Version 2 (ref. 10) or Provean Version 1.1.3 (ref. 64).
References
1. Rivera, M. N. & Haber, D. A. Wilms tumour: connecting tumorigenesis and
organ development in the kidney. Nat. Rev. Cancer 9, 699–712 (2005).
2. Beckwith, J. B., Kiviat, N. B. & Bonadio, J. F. Nephrogenic rests,
nephroblastomatosis, and the pathogenesis of Wilms Tumour. Pediatr. Pathol.
10, 1–36 (1990).
3. Beckwith, J. B. & Palmer, N. F. Histopathology and prognosis of Wilms
tumour. Results from the First National Wilms Tumour Study. Cancer 41,
1937–1948 (1978).
4. Bardeesy, N. et al. Anaplastic Wilms tumour, a subtype displaying poor
prognosis, harbours p53 gene mutations. Nat. Genet. 7, 91–97 (1994).
5. Gadd, S. et al. Clinically relevant subsets identified by gene expression patterns
support a revised ontogenic model of Wilms tumour: a Children’s Oncology
Group Study. Neoplasia 14, 742–756 (2012).
6. Walz, A. et al. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations
in favorable histology Wilms tumorus. Cancer Cell 27, 286–297 (2015).
7. Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids
Res. 29, 308–311 (2001).
8. Forbes, S. A. et al. COSMIC: Mining complete cancer genomies in the catalogue
of somatic mutations in Cancer. Nucleic Acids Res. 39, D945–D950 (2011).
9. McVean, G. A. et al. An integrated map of genetic variation from 1,092 human
genomes. Nature 491, 56–65 (2012).
10. Adzhubei, I. A. et al. A method and server for predicting damaging missense
mutations. Nat. Methods 7, 248–249 (2010).
11. Brunskill, E. W. & Potter, S. S. RNA-Seq defines novel genes, RNA processing
patterns and enhancer maps for the early stages of nephrogenesis: Hox
supergenes. Dev. Biol. 368, 4–17 (2012).
12. Wang, K. C. et al. A long noncoding RNA maintains active chromatin to
coordinate homeotic gene expression. Nature 472, 120–124 (2011).
13. Rinn, J. L. et al. Functional demarcation of active and silent chromatin domains
in human HOX loci by noncoding RNAs. Cell 129, 1311–1323 (2007).
14. Olsson, P., Motegi, A., Bera, T. K., Lee, B. & Pastan, I. PRAC2: a new gene
expressed in human prostate and prostate cancer. Prostate 56, 123–130 (2003).
15. Ellis, B. C., Molloy, P. L. & Graham, L. D. CRNDE: A Long Non-Coding RNA
Involved in CanceR, Neurobiology, and DEvelopment. Front. Genet. 3, 270 (2012).
16. Grundy, P. E. et al. Loss of heterozygosity for chromosomes 1p and 16q is an
adverse prognostic factor in favorable-histology Wilms tumour a report from the
National Wilms Tumour Study Group. J. Clin. Oncol. 23, 7312–7321 (2005).
17. Gratias, E. J. et al. Gain of 1q is associated with inferior event-free and overall
survival in patients with favorable histology Wilms tumour: a report from the
Children’s Oncology Group. Cancer 119, 3887–3894 (2013).
18. Schulze, J. M., Wang, A. Y. & Kobor, M. S. YEATS domain proteins a diverse
family with many links to chromatin modification and transcription. Biochem.
Cell Biol. 87, 65–75 (2009).
19. Li, Y. et al. AF9 YEATS domain links histone acetylation to DOT1L-mediatied
H3K79 Methylation. Cell 159, 558–571 (2014).
20. Benkert, P., Schwede, T. & Tosatto, S. C. QMEANclust: estimation of protein
model quality by combining a composite scoring function with structural
density information. BMC Struct. Biol. 9, 35 (2009).
21. Lin, C. et al. AFF4, a component of the ELL/P-TEFb elongation complex and a
shared subunit of MLL chimeras, can link transcription elongation to leukemia.
Mol. Cell 37, 429–437 (2010).
22. Yokoyama, A., Lin, M., Naresh, A., Kitabayashi, I. & Cleary, M. L. A higher-
order complex containing AFF4 and ENL family proteins with P-TEFb
facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell
17, 198–212 (2010).
23. He, N. et al. Human Polymerase-Associated Factor complex (PAFc) connects
the Super Elongation Complex (SEC) to RNA polymerase II on chromatin.
Proc. Natl Acad. Sci. USA 108, E636–E645 (2011).
24. Luo, Z., Lin, C. & Shilatifard, A. The super elongation complex (SEC) family in
transcriptional control. Nat. Rev. Mol. Cell Biol. 13, 543–547 (2012).
25. Peterlin, B. M. & Price, D. H. Controlling the elongation phase of transcription
with P-TEFb. Mol. Cell 23, 297–305 (2006).
26. Doty, R. T., Vanasse, G. J., Disteche, C. M. & Willerford, D. M. The leukemia-
associated gene Mllt1/ENL: characterization of a murine homolog and
demonstration of an essential role in embryonic development. Blood Cells Mol.
Dis. 28, 407–417 (2002).
27. Krivtsov, A. V. & Armstrong, S. A. MLL translocations, histone modifications
and leukaemia stem-cell development. Nat. Rev. Cancer 11, 823–833 (2007).
28. Slany, R. K. The molecular biology of mixed lineage leukemia. Haematologica
94, 984–993 (2009).
29. Mueller, D. et al. Misguided transcriptional elongation causes mixed lineage
leukemia. PLoS Biol. 7, e1000249 (2009).
30. Zeisig, D. T. et al. The eleven-nineteen-leukemia protein ENL connects nuclear
MLL fusion partners with chromatin. Oncogene 24, 5525–5532 (2005).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10013 ARTICLE
NATURE COMMUNICATIONS | 6:10013 | DOI: 10.1038/ncomms10013 | www.nature.com/naturecommunications 9
31. Schulze, J. M., Wang, A. Y. & Kobor, M. S. Reading chromatin: insights from
yeast into YEATS domain structure and function. Epigenetics 5, 573–577 (2010).
32. Mueller, D. et al. A role for the MLL fusion partner ENL in transcriptional
elongation and chromatin modification. Blood 110, 4445–4454 (2007).
33. Bitoun, E., Oliver, P. L. & Davies, K. E. The mixed-lineage leukemia fusion partner
AFF4 stimulates RNA polymerase II transcriptional elongation and mediates
coordinated chromatin remodeling. Hum. Mol. Genet. 16, 92–106 (2007).
34. Zhang, W., Xia, X., Reisenauer, M. R., Hemenway, C. S. & Kone, B. C. Dot1a-
AF9 complex mediates histone H3 Lys-79 hypermethylation and repression
of ENaCalpha in an aldosterone-sensitive manner. J. Biol. Chem. 281,
18059–18068 (2006).
35. Jones, B. et al. The histone H3K79 methyltransferase Dot1L is essential for
mammalian development and heterochromatin structure. PLoS Genet. 12,
e1000190 (2008).
36. Steger, D. J. et al. DOT1L/KMT4 recruitment and H3K79 methylation are
ubiquitously coupled with gene transcription in mammalian cells. Mol. Cell
Biol. 28, 2825–2839 (2008).
37. Chaudhary, K., Deb, S., Moniaux, N., Ponnusamy, M. P. & Batra, S. K. Human
RNA polymerase II-associated factor complex: dysregulation in cancer.
Oncogene 26, 7499–7507 (2007).
38. Kim, J. & Roeder, R. G. Direct Bre1-Paf1 complex interactions and RING
finger-independent Bre1-Rad6 interactions mediate histone H2B ubiquitylation
in yeast. J. Biol. Chem. 284, 20582–20592 (2009).
39. Chopra, V. S., Hong, J. W. & Levine, M. Regulation of Hox gene activity by
transcriptional elongation in Drosophila. Curr. Biol. 19, 688–693 (2009).
40. Lin, C. et al. Dynamic transcriptional events in embryonic stem cells mediated
by the super elongation complex (SEC). Genes Dev. 25, 1486–1498 (2011).
41. Luo, Z. et al. The super elongation complex family of RNA polymerase II
elongation factors gene target specificity and transcriptional output. Mol. Cell.
Biol. 32, 2608–2617 (2012).
42. Hanks, S. et al. Germline mutations in the PAF1 complex gene CTR9
predispose to Wilms tumour. Nat. Commun. 5, 4398 (2014).
43. Yoo, H.-S., Seo, J.-H. & Yoo, J.-Y. CTR9, a component of the PAF complex,
controls elongation block at the c-fos locus via signal-dependent regulation of
chromatin bound NELF dissociation. PLoS One 8, e61055 (2013).
44. Carpten, J. D. et al. HRPT2, encoding parafibromin, is mutated in
hyperparathyroidism-jaw tumour syndrome. Nat. Genet. 32, 676–680 (2002).
45. Scott, R. H., Stiller, C. A., Wlaker, L. & Rhaman, N. Syndromes and
constitutional chromosomal abnormalities associated with Wilms tumour.
J. Med. Genet. 43, 705–715 (2006).
46. Heppe, R. K., Koyle, M. A. & Beckwith, J. B. Nephrogenic rests in Wilms
tumour patients with the Drash syndrome. J. Urol. 145, 1225–1228 (1991).
47. Maiti, S., Alam, R., Amos, C. I. & Huff, V. Frequent Association of -Catenin
and WT1 Mutations in Wilms Tumours. Cancer Res. 60, 6288–6292 (2000).
48. Basu, M. & Roy, S. S. Wnt/b-catenin pathway is regulated by PITX2
homeodomain protein and thus contributes to the proliferation of human
ovarian adenocarcinoma cell, SKOV-3. J. Biol. Chem. 288, 4355–4367 (2013).
49. Kioussi, C. et al. Identification of a Wnt/Dvl/beta-Catenin --4 Pitx2 pathway
mediating cell-type-specific proliferation during development. Cell 111,
673–685 (2002).
50. Han, Y. et al. Identification and validation that up-expression of HOXA13 is a
novel independent prognostic marker of a worse outcome in gastric cancer
based on immunohistochemistry. Med. Oncol. 30, 564 (2013).
51. Guttman, M. et al. LincRNAs act in the circuitry controlling pluripotency and
differentiation. Nature 477, 295–300 (2011).
52. Prentice, R. L. A case-cohort design for epidemiologic cohort studies and
disease prevention trials. Biometrika 73, 1–11 (1986).
53. Malogolowkin, M. et al. Incidence and outcomes of patients with late
recurrence of Wilms Tumour. Pediatr. Blood Cancer 60, 1612–1615 (2013).
54. Drmanac, R. et al. Human genome sequencing using unchained base reads on
self-assembling DNA nanoarrays. Science 327, 78–81 (2010).
55. Bainbridge, M. N. et al. De novo truncating mutations in ASXL3 are associated
with a novel clinical phenotype with similarities to Bohring-Opitz syndrome.
Genome Med. 5, 11 (2013).
56. Lupski, J. R. et al. Exome sequencing resolves apparent incidental findings and
reveals further complexity of SH3TC2 variant alleles causing CMT neuropathy.
Genome Med. 5, 57–70 (2013).
57. Edmonson et al. Bambino: a variant detector and alignment viewer for
next-generation sequencing data in the SAM/BAM format. Bioinformatics 27,
865–866 (2011).
58. Pounds, S. et al. Reference alignment of SNP microarray signals for copy
number analysis of tumours. Bioinformatics 25, 315–321 (2009).
59. Brunet, J. P., Tamayo, P., Golub, T. R. & Mesirov, J. P. Metagenes and
molecular pattern discovery using matrix factorization. Proc. Natl Acad. Sci.
USA 101, 4164–4169 (2004).
60. Tusher, V., Tibshirani, R. & Chu, G. Significance analysis of microarrays
applied to transcriptionalresponses to ionizing radiation. Proc. Natl Acad. Sci.
USA 98, 5116–5121 (2001).
61. Perlman, E. J. et al. WT1 mutation and 11P15 loss of heterozygosity predict
relapse in very low-risk Wilms tumorus treated with surgery alone: a Children’s
Oncology Group Study. J. Clin. Oncol. 29, 698–703 (2011).
62. Arnold, K., Bordoli, L., Kopp, J. & Schwede, T. The SWISS-MODEL workspace:
a web-based environment for protein structure homology modelling.
Bioinformatics 22, 195–201 (2006).
63. McLaren, W. et al. Deriving the consequences of genomic variants with
Ensembl API and SNP Effect Predictor. Bioinformatics 26, 2069–2070
(2010).
64. Choi, Y., Sims, G. E., Murphy, S., Miller, J. R. & Chan, A. P. Predicting the
functional effect of amino acid substitutions and indels. PLoS ONE 7, e46688
(2012).
Acknowledgements
The TARGET initiative is supported by NCI Grant U10 CA98543. Work performed under
contracts from the National Cancer Institute, US National Institutes of Health within
HHSN261200800001E include specimen processing (the Children’s Oncology Group
Biopathology Center (BPC), whole genomic sequencing (Complete Genomics, Inc), whole
exomic sequencing (Baylor College of Medicine) and specific capture followed by
sequencing (British Columbia Cancer Agency Genome Sciences Centre). The content of
this publication does not necessarily reflect the views of policies of the Department of
Health and Human Services, nor does mention of trade names, commercial products, or
organizations imply endorsement by the US Government. The authors thank Patee
Gesuwan and Leandro Hermida and the Data Coordinating Center for their support. We
thank Karen Carty and Franceline Huser and for help and assistance with the recombinant
protein production and DSF analysis. We thank the KAUST bioscience core lab for access
to the MicroCal ITC200 microcalorimeter. We also thank the Clinical Applications of Core
Technology Laboratory of the Hartwell Center for Bioinformatics and Biotechnology of St
Jude Children’s Research Hospital for performing the copy number analysis. The authors
are grateful for the project management expertize of Karen Novik and Laura Monovich,
and for the technical expertize of Patricia Beezhold, Donna Kersey, Debbie-Payne Turner,
Mary McNulty and Yvonne Moyer. This work would not be possible without the ded-
ication of all the experts within the many disciplines both at the local institutions and
centrally within the Children’s Oncology Group. They enable the coordination and
accurate annotation required for the therapeutic and biology protocols that form the basis
for the TARGET studies. Financial Support: NCI U10 CA98543 (E.J.P., J.M.G.-F. and
M.A.M.); NIH U10CA42326 (E.J.P.); U10CA98543 (J.S.D. and E.J.P.); U24 CA114766;
UO1CA88131 (E.J.P.), the IDP Foundation (E.J.P.), the American and Lebanese Syrian
Associated Charities of St Jude (J.M. and C.M.) and the King Abdullah University of
Science and Technology (S.T.A. and A.R.).
Author contributions
D.S.G., J.M.G.A., M.A.S. and T.M.D. oversaw the administrative and data management
aspects of the TARGET project; L.J. performed the MLLT1 fragment analysis; D.M.,
C.H.H., C.N. provided the bioinformatic analysis; S.T.A. and A.R. provided the in silico
protein structure analysis and the biophysical analysis of recombinant protein; J.A.
provided the statistical analysis; J.M.G.-F. and N.R. performed the specimen processing
and quality control; J.S.D. and V.H. provided the samples and the clinical data; C.G.M.
and J.M. performed the copy number analysis; S.G. performed the gene expression
analysis; Y.M., A.J.M., R.A.M. and M.A.M. performed the target capture sequencing;
E.J.P. designed and oversaw all aspects of the study and wrote the paper with
contributions from all other authors.
Additional information
Accession codes: Whole genome and whole exome sequencing data have been deposited
in the dbGAP database under the accession code phs000471.
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing financial interests: The authors declare no competing financial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Perlman, E. J. et al. MLLT1 YEATS domain mutations
in clinically distinctive Favourable Histology wilms tumours. Nat. Commun. 6:10013
doi: 10.1038/ncomms10013 (2015).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10013
10 NATURE COMMUNICATIONS | 6:10013 | DOI: 10.1038/ncomms10013 | www.nature.com/naturecommunications
